Busulfan
Busulfan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为GATA2、Immunodeficiency、MDS。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
3 项
已进入 III/IV 期
5 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- City of Hope Medical Center
- M.D. Anderson Cancer Center
- Beam Therapeutics Inc.
- Peking University People's Hospital
- Kanglin Biotechnology (Hangzhou) Co., Ltd.
- Institute of Hematology and Blood Transfusion, Czech Republic
- Children's Hospital of Philadelphia
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、Czechia、加拿大、Puerto Rico
正在招募患者的 Busulfan 研究
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
I 期招募中美国NCT06996119High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
II 期招募中美国NCT06345495A Long-term Follow-up Study in Patients Who Received BEAM-101
不适用招募中美国NCT07373639Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
II 期 / III 期招募中中国NCT03793517Β-Thalassemia Treatment with KL003 Cell Injection
I 期 / II 期招募中中国NCT06280378Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
I 期 / II 期招募中美国NCT05327023Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
I 期 / II 期招募中CzechiaNCT07532824Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
不适用招募中中国NCT07588594MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
不适用招募中美国NCT03810196Busulfan Sample Collection Study
不适用招募中美国NCT05711732Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
II 期招募中中国NCT06816134Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
II 期招募中美国NCT06207799Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
IV 期招募中中国NCT07101588Personalized NK Cell Therapy in CBT
II 期招募中美国NCT02727803Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
II 期 / III 期招募中美国NCT04708054Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
II 期招募中美国NCT02579967Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
不适用招募中美国NCT01666080A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
不适用招募中中国NCT06879847Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
I 期 / II 期招募中美国NCT03311503Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
II 期招募中美国NCT03970096Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
I 期 / II 期招募中美国NCT04774536Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
不适用招募中中国NCT07183878Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
不适用招募中中国NCT06155188
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。